ArticleFrontiers in medicine2025
In-house chromogenic anti-factor Xa assay: development, validation, and identification of factors predicting APTT discordance.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular biomarkers in dialysis-related thrombosis and anticoagulation monitoring: thrombin-antithrombin complex, plasmin-α2-antiplasmin complex, soluble thrombomodulin, tPA/PAI-1/tPAIC, and Anti-Xa.Frontiers in medicine · 2026Review
- Case Report: Extracorporeal membrane oxygenation in acute coronary syndrome: a rare case of massive left ventricular thrombus.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Activated partial thromboplastin time (APTT) is the conventional test for monitoring unfractionated heparin (UFH) therapy, but discordance with anti-factor Xa results frequently occurs in clinical practice, potentially leading to suboptimal anticoagulation management. Objective: This study aimed to develop an in-house anti-factor Xa detection system, establish laboratory-specific APTT therapeutic ranges calibrated against anti-factor Xa levels, and identify predictors of discordance between these two monitoring methods. Methods: We developed and validated a chromogenic anti-factor Xa assay according to CLSI guidelines. From 110 patients receiving UFH, 190 samples were collected. Laboratory-specific APTT ranges were derived using linear regression and ROC analysis against anti-factor Xa target range (0.3-0.7 IU/ml). Random forest and logistic regression models identified predictors of discordance among clinical and laboratory variables. Results: The optimized assay showed excellent analytical performance with strong correlation to the commercial platform (Pearson Conclusions: This study developed a validated anti-factor Xa assay and identified substantial classification discordance between APTT and anti-factor Xa monitoring. Five clinical and laboratory factors were associated with monitoring discordance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.